ESMO 2016: A Therapeutic Update on the Management of Patients with Breast Cancer

Results from several key clinical trials evaluating new therapeutic approaches for patients with metastatic breast cancer (MBC) were presented at the European Society for Medical Oncology (ESMO) 2016 Congress on October 7–11, 2016 in Copenhagen, Denmark. These results have the potential to change clinical practice. In this activity, you will listen to two leading experts in breast cancer management and research as they review the key data presented at ESMO 2016 and discuss the implications for current practice and future research.


This activity has been designed to meet the educational needs of nurse practitioners and other health care professionals involved in the diagnosis, treatment, or management of patients with advanced breast cancer.


Upon completion of this activity, participants will be able to:

  1. Review the unmet needs in metastatic breast cancer (MBC) 
  2. Analyze clinical trial data of therapies for the treatment of breast cancer presented at ESMO 2016
  3. Develop data-driven, individualized treatment plans to improve treatment selection and outcomes for patients with breast cancer


Neil Iyengar, MD
Memorial Sloan Kettering Cancer Center, New York, USA

Hope Rugo, MD
UCSF Comprehensive Cancer Center, San Francisco, USA

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

FacultyRelationship Identified With:

Neil Iygengar, MD

No financial relationships to disclose

Hope Rugo, MD

Grant/Research Support: Amgen Inc.; Eisai Inc.; Eli Lilly and Company; Genentech, Inc.;  GSK group of companies; MacroGenics, Inc.; Merck & Co, Inc.; Novartis AG; OBI Pharma, Inc.; Pfizer Inc.; Plexxicon

Honoraria for speaking: Genomic Health, Inc.

Non-faculty: Marcel Meijer; Sandy Breslow; Alison Kemp; Leah Johnson and Bernard M. Abrams, MD hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by an independent educational grant from Eli Lilly and Company.

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education and Excerpta Medica.

CME Credit (Physicians)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Excerpta Medica. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries.  Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at Additional information on the process of converting AMA PRA Category 1 Credits™ to ECMECs® can be found at:


For all CME inquiries or special needs, please contact

Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Excerpta Medica, and Eli Lilly and Company do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician
Course opens: 
Course expires: 

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician
Please login or register to take this course.